# Retatrutide Research Overview — NextGen Peptides > A data-forward literature summary of retatrutide (LY3437943): GIP/GLP-1/glucagon triple receptor agonist mechanism, Phase 2 obesity and type 2 diabetes trial results, MASLD liver-fat data, and investigational status. An investigational GIP/GLP-1/glucagon tri-agonist whose Phase 2 weight-loss data (-24.2% at 48 weeks) are the largest published from any pharmacological compound — with Phase 3 trials currently ongoing and no regulatory approval as of mid-2026. ## The short version Retatrutide is a 39-amino-acid synthetic peptide that adds a third receptor target to the incretin framework: in addition to the GLP-1 and GIP receptors that tirzepatide already covers, it also activates the glucagon receptor. Controlled glucagon-receptor activation matters because glucagon drives thermogenesis and fat mobilization — it turns up energy expenditure in a way that GLP-1 or GIP alone cannot. The Phase 2 obesity trial (338 adults with obesity, 48 weeks) reported a mean body-weight change of -24.2% at 12 mg versus -2.1% with placebo [15]. In a parallel Phase 2 trial in type 2 diabetes, retatrutide 12 mg lowered HbA1c by -2.02% at 24 weeks and reduced body weight by -16.94% at 36 weeks [16]. A MASLD (metabolic liver disease) substudy showed -82.4% relative reduction in liver fat at 24 weeks, with 86% of participants reaching normal liver fat [14]. Critical context: retatrutide has not been approved by the FDA or any regulator as of mid-2026. These are Phase 2 figures, not the larger and longer Phase 3 trials that determine whether a drug receives approval. Phase 3 data are pending. This page reports the published research only; it is not medical advice and lists no dose. ## What it is Retatrutide (also known by its research identifier LY3437943) is a linear 39-amino-acid synthetic peptide built on a GIP-sequence backbone with a C20 fatty diacid acylated for albumin binding, enabling once-weekly dosing. Its molecular formula is C221H342N46O68 (free acid). It is described in the pharmacology literature as a GGG tri-agonist or triple-hormone-receptor agonist. Cryo-EM structural work resolved its simultaneous engagement of all three receptors at near-atomic resolution: it is approximately 8.9 times more potent at GIPR than native GIP, but approximately 0.3-fold (GCGR) and 0.4-fold (GLP-1R) relative to the endogenous hormones at those receptors, calibrating the glucagon signal to be stimulatory without being hyperglycemic [13]. It remains investigational — in Phase 3 trials (the TRIUMPH series) as of mid-2026, with no approved indication. ## How it works Retatrutide is a single-molecule agonist at three receptors simultaneously: GLP-1R, GIPR, and GCGR. The GLP-1 and GIP arms drive the same mechanisms as the approved agents: glucose-dependent insulin secretion, glucagon suppression, appetite reduction via hypothalamic circuits, and gastric emptying delay. The glucagon receptor arm adds what those two cannot: thermogenesis (burning more energy as heat via hepatic and adipose mechanisms) and increased fat mobilization from adipose tissue. In animal models and mechanistic studies, glucagon receptor activation also improves hepatic lipid clearance — the mechanism proposed to explain the MASLD liver-fat reductions. The cryo-EM structural study confirmed that all three receptors are simultaneously engaged and characterized the relative potencies: the calibrated glucagon signal (0.3-fold relative to native glucagon) is strong enough to add metabolic activation without the full hyperglycemia risk of a potent glucagon agonist [13]. ## What the research shows *Phase 2 obesity trial.* In 338 adults with obesity (BMI ≥30, or ≥27-<30 with comorbidity; 51.8% men), once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% at 48 weeks versus -2.1% with placebo. GI adverse events were dose-related and mostly mild-to-moderate; heart rate increased in a dose-dependent fashion, peaking at approximately 24 weeks [15]. *Phase 2 type 2 diabetes trial.* In 281 adults with type 2 diabetes, retatrutide 12 mg lowered HbA1c by -2.02% at 24 weeks (versus -0.01% placebo) and reduced body weight by -16.94% at 36 weeks (versus -3.00% placebo). Mild-to-moderate GI adverse events occurred in 35% of participants; no severe hypoglycemia and no deaths were reported [16]. *MASLD (metabolic liver disease) substudy.* In 98 participants with obesity/overweight and MASLD (≥10% liver fat by MRI, no type 2 diabetes), retatrutide 12 mg produced a relative liver-fat reduction of -82.4% at 24 weeks (versus +0.3% with placebo), with 86% of participants reaching normal liver fat (<5%); reductions were sustained to 48 weeks (-86.0% at 12 mg) [14]. *Triple-receptor structural confirmation.* Cryo-EM of retatrutide bound to all three receptor complexes confirmed simultaneous triple agonism and resolved the binding geometry and relative potencies at near-atomic resolution (2.68/3.26/2.84 Å for GLP-1R, GIPR, and GCGR respectively) [13]. *Narrative synthesis.* A 2025 review characterizes the Phase 2 mean ~24% weight loss as a step-change versus prior incretin therapies and outlines the ongoing Phase 3 TRIUMPH program [12]. ![Retatrutide triple-receptor structural motif illustration in cold cobalt](/images/retatrutide.webp) ## Reported effects, cautions & safety Community reports from research-use communities give a qualitative picture of retatrutide that largely mirrors Phase 2 trial findings, with some distinctions from the approved agents. **Frequently reported benefits:** near-total quieting of food noise (described as more abrupt than with prior incretin agents); rapid and pronounced weight reduction; mild thermogenic warmth attributed in community discussion to the glucagon receptor arm; improved sense of well-being and lighter relationship with food. These are anecdotal, unverified reports from research-use communities with no confirmed doses or clinical oversight — not clinical findings. **Frequently reported adverse effects:** nausea, peaking 4-8 hours post-administration in the early weeks; elevated resting heart rate, with community reports of 5-15 bpm above baseline tracking the Phase 2 trial signals; sulfur burps; constipation; fatigue in the initial weeks; occasional sleep disturbances; injection-site itching. These are anecdotal, unverified reports alongside the documented Phase 2 signals. **Cited safety cautions from the literature:** - Retatrutide is unapproved; research-channel sources carry documented identity, purity, and sterility risks distinct from any clinical-trial formulation [12]. - Dose-dependent GI adverse events (nausea in up to 45% at highest Phase 2 dose) drove 18% discontinuation at that dose level [15]. - Dose-dependent heart-rate increases (approximately 5-7 bpm at peak; GCGR-mediated cardiac chronotropy); long-term cardiovascular effects are under investigation in dedicated ongoing trials [15]. - Hypoglycemia risk when combined with insulin or sulfonylureas (Phase 2 diabetic participants required insulin de-escalation) [16]. - Lean-mass loss alongside fat mass; resistance training and adequate protein are emphasized in research discussions as protective strategies. - Long-term safety, durability after discontinuation, and cardiovascular/kidney outcomes are unknown; all pivotal outcome trials are ongoing as of mid-2026. ## Where it fits Retatrutide is at the frontier of the incretin class — the furthest along the receptor-target progression (triple vs dual vs single agonism) and carrying the largest weight-loss numbers in published Phase 2 data. The gap between its Phase 2 figures and those of [tirzepatide](/tirzepatide) is approximately 4 percentage points (-24.2% vs -20.9%), and the compounds were not compared head-to-head in the same trial. Its Phase 3 program (TRIUMPH) is ongoing; no head-to-head against approved agents has reported, and it carries a higher uncertainty load than either of the approved compounds on this desk. The [comparison page](/compare) places its Phase 2 data alongside the Phase 3 numbers for semaglutide and tirzepatide, with that design difference explicitly noted. --- A literature digest of peer-reviewed incretin research — effect sizes reported as published, not as clinical guidance.